Company intelligence / Profile preview

Edinburgh Biosciences

Grangemouth, Scotland, UKedinburghbiosciences.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Edinburgh Biosciences has developed Revisyon, a non-invasive light-based diagnostic and therapeutic system targeting cataracts. The solution aims to replace or reduce the need for surgical intervention by reversing protein aggregation in the eye lens. As of mid–2025, it remains under patient trials with plans to commercialize in early 2026; no published clinical results are available yet.

Therapeutic areas: Ophthalmology
Modalities: DeviceLight-based therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Revisyon

Phase 1

Indications: Cataracts

Beyond the preview

Go deeper on Edinburgh Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Edinburgh Biosciences.

Explore the full profile